Berlin, Germany, October 17, 2023, 7:00 p.m. CEST – TME Pharma NV (Euronext Growth Paris: ALTME), a biotechnology company specializing in the development of novel therapies for the treatment of cancer by targeting the tumor microenvironment (TME), announces today today the end of the six-month soft lock-up period for shares and the end of the lock-up for convertible bonds following the financial transaction announced on April 18, 2023.
To receive all of the company’s financial communications in real time, please register directly by email to the following address: [email protected]